BOK Financial’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.65M | Buy |
5,935
+68
| +1% | +$31.7K | 0.04% | 285 |
|
|
2025
Q4 | $2.66M | Sell |
5,867
-1,171
| -17% | -$505K | 0.04% | 284 |
|
|
2025
Q3 | $2.76M | Sell |
7,038
-1,216
| -15% | -$508K | 0.04% | 291 |
|
|
2025
Q2 | $3.67M | Buy |
8,254
+1,154
| +16% | +$532K | 0.06% | 245 |
|
|
2025
Q1 | $3.44M | Sell |
7,100
-685
| -9% | -$319K | 0.06% | 243 |
|
|
2024
Q4 | $3.19M | Sell |
7,785
-68
| -0.9% | -$31.5K | 0.05% | 255 |
|
|
2024
Q3 | $3.56M | Sell |
7,853
-150
| -2% | -$72.1K | 0.06% | 248 |
|
|
2024
Q2 | $3.75M | Sell |
8,003
-2,229
| -22% | -$967K | 0.07% | 244 |
|
|
2024
Q1 | $4.3M | Sell |
10,232
-9,274
| -48% | -$3.92M | 0.08% | 236 |
|
|
2023
Q4 | $7.94M | Sell |
19,506
-100
| -0.5% | -$36.9K | 0.16% | 143 |
|
|
2023
Q3 | $7.1M | Buy |
19,606
+394
| +2% | +$138K | 0.16% | 145 |
|
|
2023
Q2 | $6.76M | Sell |
19,212
-769
| -4% | -$259K | 0.14% | 160 |
|
|
2023
Q1 | $6.3M | Sell |
19,981
-3,157
| -14% | -$947K | 0.13% | 166 |
|
|
2022
Q4 | $6.68M | Buy |
23,138
+16,308
| +239% | +$4.97M | 0.12% | 167 |
|
|
2022
Q3 | $1.98M | Sell |
6,830
-78
| -1% | -$22.4K | 0.04% | 359 |
|
|
2022
Q2 | $1.95M | Sell |
6,908
-4,668
| -40% | -$1.25M | 0.04% | 378 |
|
|
2022
Q1 | $3.02M | Sell |
11,576
-12
| -0.1% | -$2.85K | 0.05% | 310 |
|
|
2021
Q4 | $2.54M | Sell |
11,588
-1,445
| -11% | -$281K | 0.04% | 353 |
|
|
2021
Q3 | $2.36M | Buy |
+13,033
| New | +$2.54M | 0.04% | 358 |
|
|
2021
Q1 | $3.62M | Sell |
16,825
-25,204
| -60% | -$5.54M | 0.07% | 277 |
|
|
2020
Q4 | $9.93M | Sell |
42,029
-1,504
| -3% | -$345K | 0.19% | 119 |
|
|
2020
Q3 | $11.8M | Sell |
43,533
-5,090
| -10% | -$1.4M | 0.26% | 90 |
|
|
2020
Q2 | $14.1M | Sell |
48,623
-131
| -0.3% | -$35.5K | 0.33% | 71 |
|
|
2020
Q1 | $11.6M | Buy |
48,754
+4,737
| +11% | +$1.09M | 0.33% | 75 |
|
|
2019
Q4 | $9.64M | Buy |
44,017
+13,505
| +44% | +$2.73M | 0.22% | 110 |
|
|
2019
Q3 | $5.17M | Sell |
30,512
-13,149
| -30% | -$2.33M | 0.12% | 187 |
|
|
2019
Q2 | $8.01M | Buy |
43,661
+4,459
| +11% | +$780K | 0.19% | 122 |
|
|
2019
Q1 | $7.21M | Buy |
39,202
+4,514
| +13% | +$834K | 0.17% | 143 |
|
|
2018
Q4 | $5.75M | Buy |
34,688
+20,469
| +144% | +$3.55M | 0.16% | 142 |
|
|
2018
Q3 | $2.74M | Buy |
14,219
+7,780
| +121% | +$1.39M | 0.07% | 309 |
|
|
2018
Q2 | $1.09M | Buy |
6,439
+2,637
| +69% | +$409K | 0.03% | 471 |
|
|
2018
Q1 | $619K | Buy |
3,802
+1,946
| +105% | +$318K | 0.02% | 585 |
|
|
2017
Q4 | $278K | Sell |
1,856
-359
| -16% | -$53.2K | 0.01% | 800 |
|
|
2017
Q3 | $336K | Sell |
2,215
-256
| -10% | -$38.5K | 0.01% | 767 |
|
|
2017
Q2 | $319K | Buy |
+2,471
| New | +$297K | 0.01% | 734 |
|
|
2013
Q4 | – | Sell |
-2,681
| Closed | -$203K | – | 897 |
|
|
2013
Q3 | $203K | Buy |
2,681
+120
| +5% | +$9.55K | 0.01% | 780 |
|
|
2013
Q2 | $205K | Buy |
+2,561
| New | +$189K | 0.01% | 766 |
|
Other funds holding VRTX
VCM
VPM
BOK Financial's VRTX Position: Q1 2026 in Review
BOK Financial increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q1 2026, buying an estimated $31.7K and bringing the position to 5,935 shares worth $2.65M. The position accounts for 0.04% of the portfolio, ranked #285.
BOK Financial first reported a position in VRTX in Q2 2013 and has held it in 37 quarters since. The position peaked at $14.1M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- BOK Financial held 5,935 shares of Vertex Pharmaceuticals worth $2.65M as of Q1 2026.
- BOK Financial bought 68 Vertex Pharmaceuticals shares in Q1 2026, an estimated $31.7K.
- Vertex Pharmaceuticals made up 0.04% of BOK Financial's portfolio in Q1 2026, its #285 holding.
- BOK Financial first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- BOK Financial's Vertex Pharmaceuticals position peaked at $14.1M in Q2 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on BOK Financial's 13F filing for Q1 2026, filed 8 May 2026.